Osteoporosis Market Research Reports & Industry Analysis
Osteoporosis is characterized by decreased bone mineral density (BMD) and deterioration of the bone microarchitecture, a combination of factors that lead to an increased risk of fracture. Osteoporosis affects hundreds of millions of people worldwide, in developed and undeveloped nations. The prevalence of osteoporosis is projected to increase considerably as the global population ages and life expectancy increases as anticipated. The Office of the Surgeon General in the U.S. warns that osteoporosis may become an epidemic if people do not make the adjustments in nutrition, supplementation, and physical activity necessary to prevent osteoporosis.
The overall cost of osteoporosis fractures and their complications poses a considerable burden for healthcare systems around the world; osteoporosis costs are comparable with those of other major chronic diseases, such as cardiovascular diseases and asthma. In addition, osteoporosis fractures are a major cause of disability and morbidity among older people; an estimated fifth of patients who experience an osteoporotic hip fracture die due to complications within 1 year after the fracture. Drug therapies that are capable of addressing osteoporosis and reducing the risk of fractures could bring economic benefits to governments and healthcare providers and improve the quality of life for osteoporosis patients.
Osteoporosis Industry Research & Market Reports
-
Zilosul Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... yields glucurono-xylans, which are then sulfated to create a negatively charged substance that resembles glycosaminoglycans (GAGs). GAGs are complex carbohydrates that interact with proteins involved in inflammatory processes, thereby regulating various bodily functions. PPS is ... Read More
-
X0002 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... (OA) and rheumatoid arthritis. This novel drug is being evaluated for its effectiveness in delivering pain relief and anti-inflammatory effects directly through the skin. A Phase III clinical trial, TF-X0002-31 (Freedom-1), has been initiated at ... Read More
-
Wegovy Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... reducing food consumption, and lowering calorie intake. Semaglutide has received approval from the US FDA for long-term weight management in adults who are obese or overweight with at least one weight-related condition, such as hypertension, ... Read More
-
Tlc599 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... relief. TLC599 offers the benefit of locally delivering a powerful, clinically validated steroid that typically has a short half-life, providing both immediate and sustained effects. This emerging therapy presents several advantages, including rapid pain relief, ... Read More
-
Sprifermin Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... It is administered through injections directly into the joint, typically every 6 to 12 months. Notably, sprifermin is the first recombinant form of FGF18 shown to promote cartilage growth in a controlled clinical trial, positioning ... Read More
-
Rtx-grt7039 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... Potential Vanilloid 1 (TRPV1) receptor operates through a well-established mechanism and is administered directly into the joint via intra-articular injection. As osteoarthritis patients increasingly seek effective alternatives to traditional osteoarthritis treatments, RTX-GRT7039 offers a promising ... Read More
-
Renu Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... the fetus and acting as a barrier between mother and baby. Amniotic tissue has been used in medical treatments for over a century due to its healing properties. ReNu is rich in anti-inflammatory cytokines, regenerative ... Read More
-
Mm-ii Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... multilamellar liposomes alongside an innovative mechanism of action to deliver long-lasting symptomatic relief. Extensive pre-clinical research has confirmed the safety and lubricating effects of MM-II, which help to minimize joint friction and cartilage wear. Additionally, ... Read More
-
Lorecivivint Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... (DMOAD). Preclinical studies with vehicle-controlled models suggest that lorecivivint may act through a dual mechanism, providing three key benefits for joint health: promoting cartilage regeneration, slowing cartilage degradation, and reducing inflammation. These effects are increasingly ... Read More
-
Lna043 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... This drug is being explored as a potential groundbreaking disease-modifying therapy for osteoarthritis. LNA043 is part of Novartis’s early investigational efforts aimed at addressing cartilage damage and reducing inflammation associated with osteoarthritis. This drug, which ... Read More
-
Jta-004 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... of hyaluronic acid and plasma protein, substances naturally present in the synovial fluid of joints, along with a fast-acting analgesic. JTA-004 aims to improve joint lubrication, protect cartilage in osteoarthritic joints, and deliver effective pain ... Read More
-
Invossa Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... States and globally have demonstrated that INVOSSA can significantly relieve pain, improve mobility, and potentially slow osteoarthritis progression while enhancing joint structure. As an allogeneic, off-the-shelf therapy, it presents a promising alternative to traditional osteoarthritis ... Read More
-
Elixcyte Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... supporting the normal function of damaged chondrocytes. This therapy for osteoarthritis also helps alleviate pain and maintain the normal structure of cartilage. By harnessing the regenerative power of stem cells, ELIXCYTE promotes tissue repair and ... Read More
-
Cntx-4975 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... trans-capsaicin administered via injection directly to the pain site. This innovative treatment harnesses capsaicin’s natural analgesic properties, aiming to provide rapid, long-lasting, and targeted pain relief. CNTX-4975 further works by targeting the TRPV1 receptor, which ... Read More
-
Hyaluronic Acid
... CAGR of 7.9% over the analysis period 2023-2030. Offline Distribution Channel, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$1.6 Billion by the end of the ... Read More
-
Amz001 Osteoarthritis Drug Pipeline – Market Insights And Forecasts Up to 2032
... sodium, AMZ001 stands out in the osteoarthritis medication landscape due to its targeted approach, offering effective localized pain relief with a single daily application (QD). Its targeted design helps reduce systemic exposure and minimizes the ... Read More
-
Global Stem Cell Therapy for Osteoarthritis Market 2024 by Company, Regions, Type and Application, Forecast to 2030
... progressive to joint stiffness, swelling, pain, and loss of mobility. The prevalence rate of OA is extremely high, affecting more than 250 million people worldwide. With increases in the aging and obese populations, the prevalence ... Read More
-
Injection Pen Market by Type (Disposable and Reusable Pens), Therapy (Diabetes Therapy (Insulin, GLP-1), Growth Hormone Therapy, Osteoporosis, obesity, fertility), End User (Homecare and Hospitals & Clinics), and Region - Global Forecast to 2030
... global injection pen market is projected to reach USD 74.1 billion by 2030 from USD 47.0 billion in 2024, at a CAGR of 7.9% during the forecast period. The rapid growth in the geriatric population ... Read More
-
Bone Densitometer Market Report by Device Type (Axial Bone Densitometers, Peripheral Bone Densitometers), Technology (Dual-Energy X-Ray Absorptiometry (DXA), Single X-Ray Absorptiometry (SXA), Radiographic Absorptiometry (RA), Quantitative Computed Tomography (QCT), and Others), Application (Osteoporosis and Osteopenia Diagnosis, Cystic Fibrosis Diagnosis, Body Composition Measurement, Rheumatoid Arthritis Diagnosis, and Others), End-User (Hospitals & Specialty Clinics, Diagnostics and Imaging Centers, and Others), and Region 2024-2032
... Diagnosis, Cystic Fibrosis Diagnosis, Body Composition Measurement, Rheumatoid Arthritis Diagnosis, and Others), End-User (Hospitals & Specialty Clinics, Diagnostics and Imaging Centers, and Others), and Region 2024-2032 The global bone densitometer market size reached US$ 307.6 ... Read More
-
Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutics (Non-Hormonal Therapy and Hormonal Therapy), By Indication (Contraception, Gynecology Infections, Female Infertility, Postmenopausal disorders, Polycystic Ovary Syndrome, Osteoporosis, Gynecology Cancer, Endometriosis, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Competition, 2019-2029F
... Endometriosis, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Region and Competition, 2019-2029F Global Gynecology Drugs Market was valued at USD 5.74 Billion in 2023 and is anticipated to project impressive growth ... Read More
-
Women Healthcare Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, ORTHO TRI-CY LO (28)), By Application (Hormonal Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome, Others), By Region and Competition, 2019-2029F
... Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome, Others), By Region and Competition, 2019-2029F Global Women Healthcare Market was valued at USD 9.52 Billion in 2023 and is anticipated to project steady growth in ... Read More
-
Bone Densitometers
... at a CAGR of 5.5% over the analysis period 2023-2030. Axial Bone Densitometers, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$264.5 Million by the end ... Read More
-
Osteoporosis Therapeutics
... at a CAGR of 2.8% over the analysis period 2023-2030. Bisphosphonates Drug Class, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$8.1 Billion by the end ... Read More
-
Global Osteoporosis Drugs Market Report by Route of Administration (Injectable, Oral, Others) Product Type (Rank Ligand Inhibitor, Bisphosphonates, Calcitonin, Parathyroid Hormone Therapy (PTH), Selective Estrogen Receptor Modulators (SERMs), Sclerostin Inhibitor, Others) Countries and Company Analysis, 2024-2032
... 2024-2032 Osteoporosis Drugs Market Analysis The osteoporosis drugs market is expected to over US$ 25.53 billion by 2032 from US$ 17.43 billion by 2023, with a CAGR growth of 4.33% from 2024 to 2032 because ... Read More
-
Osteoporosis: Seven-Market Drug Forecast and Market Analysis
... as a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, predisposing a person to bone fragility and susceptibility to fracture. Common sites of fracture include the spine, hip, distal ... Read More
Research Assistance
